Compounded vs brand GLP-1: what's the difference, and is it legal?

Brand vs compounded, defined

The two are not the same product, and it helps to be precise about how they differ before getting to the legal question.

Is compounding GLP-1 medication legal?

Drug compounding is a long-standing, legal part of US pharmacy practice. The FDA explains that compounding is generally the combining or altering of ingredients to create a medication tailored to an individual patient, and that it is governed by two sections of the Federal Food, Drug, and Cosmetic (FD&C) Act:

• Section 503A covers compounding by a licensed pharmacist in a state-licensed pharmacy (or by a licensed physician) for an individual patient, generally based on a prescription.
• Section 503B covers 'outsourcing facilities' that register with the FDA and must follow current good manufacturing practice (CGMP) standards.

Compounded drugs made under these sections are exempt from FDA pre-market approval. That is why they can be lawful to prepare and dispense, and at the same time are correctly described as 'not FDA-approved.' Per the FDA, compounded drugs are not reviewed by the agency for safety, effectiveness, or quality before they reach patients.

The legal picture depends on the specific drug, the pharmacy, and your individual prescription, and it changes over time. This page is general information, not legal advice. A licensed provider and pharmacy determine what is appropriate and permissible for you.

What changed when the GLP-1 shortages ended

For much of 2023 and 2024, semaglutide and tirzepatide were on the FDA's drug-shortage list. During a shortage, the law gives compounders more room to prepare copies of a drug that is otherwise commercially unavailable. That is a large part of why compounded GLP-1s became so widely available.

The FDA then determined the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025. As supply stabilized, the FDA clarified its policies for compounders, and the broad shortage-era allowance to mass-produce copies no longer applies. The agency has also proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list.

Compounding has not simply ended, though. It can still be appropriate when a licensed provider documents a specific clinical need for an individual patient that the approved product does not meet, for example a different formulation or dose. The key shift is from 'widely available because of a shortage' to 'individualized, prescription-driven, and case-specific.' What is permissible for any given patient is a decision for the provider and pharmacy, working within current FDA rules.

What this means for you, and how Expert Health approaches it

If you are considering a GLP-1, the honest version is this: brand and compounded are different products with different regulatory status, and the right choice depends on your situation, your insurance, and a provider's judgment. Expert Health's approach is to keep that decision where it belongs:

• A US-licensed provider reviews your history and decides whether a brand or compounded option is appropriate, or whether treatment is appropriate at all.
• Compounding, when used, is done by an FDA-regulated US pharmacy on an individual prescription.
• Expert Health states plainly that compounded medications are not FDA-approved, rather than implying they are the same as the brand.
• Pricing is transparent, so you can weigh brand coverage against the compounded cost with real numbers.

For prices, see tirzepatide cost and semaglutide cost. To check the clinic itself, see is Expert Health legit.

Frequently asked questions

Sources

1. Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration
2. FD&C Act Provisions that Apply to Human Drug Compounding (503A and 503B) · U.S. Food and Drug Administration
3. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize · U.S. Food and Drug Administration
4. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List · U.S. Food and Drug Administration